journal article·2018-10-24

Cancer Chemoradiotherapy Duo: Nano-Enabled Targeting of DNA Lesion Formation and DNA Damage Response

Wei Jiang, Quan Li, Zhengchun Zhu, Qin Wang, Jiaxiang Dou, Yingming Zhao, Weifu Lv, Fei Zhong, Yandan Yao, Guoqing Zhang, Hang Liu, Yucai Wang, Jun Wang

ACS Applied Materials & Interfaces· Volume 10· Issue 42
Publisher page

Abstract

Both production of DNA damage and subsequent prevention of its repair are crucial in concluding the therapeutic outcome of radiotherapy (RT). However, nearly all current strategies for improving RT focus only on one of the two aspects and overlook the necessity of their combinations. In this work, we introduce a concept of DNA-dual-targeting nanomedicine (NM) to simultaneously enhance DNA lesion formation and prevent the succeeding repair. Briefly, the cisplatin prodrug loaded in NM can form platinated DNA in cell nuclei, making DNA more vulnerable to the ionizing radiation generated by RT. Concomitantly, the spatial-temporally codelivered vorinostat, a histone deacetylase inhibitor, prolongs the build-up of double-strand breaks and causes cell apoptosis en masse, probably due to the suppressed expression of DNA repair proteins. Furthermore, this nanoplatform is suitable for fluorescence and magnetic resonance imaging techniques, enabling accurate trafficking of the NM as well as reliable real-time imaging-guided precision RT. Finally, results from in vitro and in vivo jointly reveal that this dual-action system attains a remarkably enhanced radiotherapeutic outcome. In conclusion, our imaging-guided DNA-dual-targeting design represents a novel strategy for efficient cancer precision RT.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Histone Deacetylase Inhibitors Research · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China

Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China

Department of Radiotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

Department of Oncology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China

Institutes for Life Sciences, School of Medicine and National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, China

Funding

Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China

References (59)

Show source-provided references
1. 10.1038/nrclinonc.2015.12010.1038/nrclinonc.2015.120 ↗
2. 10.1002/cncr.2132410.1002/cncr.21324 ↗
3. 10.1038/nature1076010.1038/nature10760 ↗
4. 10.1038/nrc395810.1038/nrc3958 ↗
5. 10.1038/nrc258710.1038/nrc2587 ↗
6. 10.1038/nrc260310.1038/nrc2603 ↗
7. 10.1038/nrclinonc.2012.20310.1038/nrclinonc.2012.203 ↗
8. 10.1016/j.biomaterials.2016.12.01010.1016/j.biomaterials.2016.12.010 ↗
9. 10.1021/acsnano.5b0747310.1021/acsnano.5b07473 ↗
10. 10.1021/acsami.6b1013210.1021/acsami.6b10132 ↗
11. 10.1021/acsami.7b0111210.1021/acsami.7b01112 ↗
12. 10.1021/acsami.6b0839110.1021/acsami.6b08391 ↗
13. 10.1021/acsami.5b1158810.1021/acsami.5b11588 ↗
14. 10.1021/acsami.6b1349310.1021/acsami.6b13493 ↗
15. 10.1016/j.biomaterials.2016.10.02010.1016/j.biomaterials.2016.10.020 ↗
16. 10.1021/nn405773r10.1021/nn405773r ↗
17. Mcilwrath A. J. · Cancer Res. · 1994 · 54 · 3718
18. 10.1021/acsami.7b0959910.1021/acsami.7b09599 ↗
19. 10.1038/nrc300710.1038/nrc3007 ↗
20. 10.1038/nrclinonc.2016.7910.1038/nrclinonc.2016.79 ↗
21. 10.1038/nrc318510.1038/nrc3185 ↗
22. 10.1021/nn203165z10.1021/nn203165z ↗
23. 10.1038/nrc234210.1038/nrc2342 ↗
24. 10.1038/nrc389110.1038/nrc3891 ↗
25. 10.1016/j.dnarep.2009.04.01110.1016/j.dnarep.2009.04.011 ↗
26. 10.1038/nrc.2015.210.1038/nrc.2015.2 ↗
27. 10.1038/nature0523610.1038/nature05236 ↗
28. 10.1016/j.currproblcancer.2017.04.00210.1016/j.currproblcancer.2017.04.002 ↗
29. 10.1002/anie.20160893610.1002/anie.201608936 ↗
30. 10.1073/pnas.130395811010.1073/pnas.1303958110 ↗
31. 10.1016/j.biomaterials.2018.03.05510.1016/j.biomaterials.2018.03.055 ↗
32. 10.1016/j.jconrel.2017.09.00710.1016/j.jconrel.2017.09.007 ↗
33. 10.1016/j.canlet.2012.09.01810.1016/j.canlet.2012.09.018 ↗
34. 10.1038/nrd436010.1038/nrd4360 ↗
35. 10.1016/j.addr.2015.10.02210.1016/j.addr.2015.10.022 ↗
36. 10.1002/adma.20160662810.1002/adma.201606628 ↗
37. 10.1002/adma.20140471510.1002/adma.201404715 ↗
38. 10.1021/acsami.7b0301710.1021/acsami.7b03017 ↗
39. 10.1021/acsami.6b1520010.1021/acsami.6b15200 ↗
40. 10.1021/am503846p10.1021/am503846p ↗
41. 10.1021/acsnano.8b0150810.1021/acsnano.8b01508 ↗
42. 10.1016/j.nantod.2016.04.00810.1016/j.nantod.2016.04.008 ↗
43. 10.1007/s12274-017-1925-410.1007/s12274-017-1925-4 ↗
44. 10.1002/smll.20140286510.1002/smll.201402865 ↗
45. 10.1021/ja211035w10.1021/ja211035w ↗
46. 10.1021/acsnano.5b0509710.1021/acsnano.5b05097 ↗
47. 10.1039/c4nr03693j10.1039/c4nr03693j ↗
48. 10.1038/nature0348210.1038/nature03482 ↗
49. 10.1016/j.biomaterials.2015.02.01510.1016/j.biomaterials.2015.02.015 ↗
50. 10.1038/nrd77210.1038/nrd772 ↗
51. 10.1016/j.clon.2014.01.00910.1016/j.clon.2014.01.009 ↗
52. 10.1073/pnas.100852210710.1073/pnas.1008522107 ↗
53. 10.1021/acsnano.5b0582510.1021/acsnano.5b05825 ↗
54. 10.1038/nrclinonc.2012.19410.1038/nrclinonc.2012.194 ↗
55. 10.1021/acsami.7b0716710.1021/acsami.7b07167 ↗
56. 10.1021/acs.chemrev.7b0025810.1021/acs.chemrev.7b00258 ↗
57. 10.1002/adma.20150022910.1002/adma.201500229 ↗
58. 10.1021/acsami.5b0927410.1021/acsami.5b09274 ↗
59. 10.1021/acsami.5b0693810.1021/acsami.5b06938 ↗